Guillermo Méndez

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly, Jaffer A. Ajani, Thomas Zander et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

Development without germ cells: The role of the germ line in zebrafish sex differentiation

Krasimir Slanchev, Jürg Stebler, Guillermo Méndez et al. · Proceedings of the National Academy of Sciences · 2005 · 345 citations · Full text

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Thierry André, Elena Élez, Eric Van Cutsem et al. · New England Journal of Medicine · 2024 · 158 citations